Recon Strategy
Contact

Insights

Fifteen+ years of
healthcare thinking.

Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.

ESSENTIAL READING

  • Biopharma, Payers, Institutional

Outcomes Based Arrangements in Biopharma

Today’s advanced therapies target devastating diseases with high unmet need. Given the urgent medical need (and pressure from patient advocates), regulators increasingly must make decisions based on early, incomplete data when it comes to durability, real-world effectiveness, and cost-effectiveness – all while bearing costs that can exceed $1 million per patient.
  • Biopharma

A few thoughts about navigating biopharma macro scenarios

Planning biopharma strategies against a robust set of macro-scenarios will be crucial to mid- and long-term success. While historically these scenarios have revolved around targeted issues, the current challengescall for a more expansive - and likely more difficult - set of questions to be asked.
  • Biopharma, Payers, Providers, Medtech, Digital

Why the Best AI Won’t Win in Healthcare

As advanced AI becomes widely accessible, healthcare companies can no longer rely on superior technology alone for lasting advantage. Instead, they need a coherent AI strategy built around five interconnected choices. Harvard Business Review article.
Sector
All
NEJM opinion

Can doulas help with our maternal health crisis? Promises and obstacles to impact

  • Digital , 
This post, by a high school senior who spent the summer with Recon Str…

Read more

A Kaplan-Meier view of oncology development

  • Biopharma , 
  • Digital , 
We refresh a prior analysis of two cohorts of oncology development pro…

Read more

The New England Journal of Medicine

An opinionated take on NEJM highlights for the second quarter of 2024

  • NEJM
The quest for solid tumor CAR-T For all their success in hematological…

Read more

Walmart Health didn’t test the opportunity in rural underserved markets

  • Providers
What lessons can be drawn from Walmart’s precipitous shut down of its …

Read more

Beyond drug supply: BIOSECURE and early-stage drug R&D

  • Biopharma
A PDF version can be downloaded here. One of the major aims of the pro…

Read more

The New England Journal of Medicine

An opinionated take on NEJM highlights for the first quarter of 2024

  • NEJM
Hitting reset for the immune system Every time I get into a new issue …

Read more

Average deal values

Trends in biotech deals in 2022 and 2023: oncology vs. the rest

  • Biopharma
Summary After challenging conditions in 2022, deal-driven biotech spen…

Read more

The New England Journal of Medicine

An opinionated take on NEJM highlights for the fourth quarter of 2023

  • NEJM
A Chinese study uncovers a new use for an old drug Bleeding in the sma…

Read more

Multi-Cancer Early Detection tests – Will they become part of regular clinical care?

PDF here Summary The idea of a single blood-test to detect many cancer…

Read more

SELECTED ENGAGEMENTS

Insight, put to work

Our published thinking is one half of the picture. These are representative client engagements, anonymized — each tagged by sector, so you can trace the path from perspective to practice.

  • Institutional

Strategy for Statewide Health Information Exchange

A non-profit health information exchange was facing financial struggles and needed a new strategy that would keep it financially sustainable

HIE, Health IT,

  • Medtech, Early Stage

Growth strategy for point-of-care testing

Post pandemic an innovative diagnostics platform company wanted to dramatically increase its market by targeting retail clinics for its point-of-care diagnostics platform

Growth, product market fit, value proposition

  • Institutional

University Trials

Large university wanting to dramatically increase its clinical research footprint

Keep up with Recon Strategy Insights
Get an email each time we publish a new article